Nashville, TN Clinical Trials Report — April 2026

For Nashville residents considering clinical trial participation, April 2026 presents a critical window to join studies before enrollment concludes. A total of 72 clinical trials are slated to close within the next 90 days in the city. This urgency is particularly relevant for healthy volunteers, as 7 of these rapidly closing studies are still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly.

Nashville currently hosts 1,258 clinical trials actively recruiting across 430 research facilities, offering a wide range of opportunities for patients and healthy volunteers alike.

Impending Deadlines for Research Participation

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cancers, neurological conditions, and kidney health are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Multiple system atrophy (2 trials)
• Advanced solid tumor (2 trials)
• Ewing sarcoma (2 trials)
• Metastatic breast cancer (2 trials)
• Solid tumors (2 trials)
• Advanced solid tumors (2 trials)
• Acute kidney injury (2 trials)
• Breast cancer (2 trials)
• Advanced breast cancer (2 trials)
• Long COVID (2 trials)

New Research Opportunities in Nashville

This month, Nashville saw the opening of 13 new clinical trials, a slight increase from the 11 trials that launched in March 2026. These new studies bring fresh opportunities across various medical fields, with a strong focus on drug development.

Among the new trials, 6 are drug trials, 2 are biological studies, and 2 involve medical devices. Other new trials include a behavioral study and a procedure-based study. Conditions being explored in these new trials range from specific cancers to broader health concerns:

• AAOCA
• Acute respiratory failure
• Aging
• Castration-resistant prostate cancer
• Cognitive symptoms
• Colorectal cancer
• Cutaneous melanoma
• Depression
• Esophageal adenocarcinoma
• Esophageal cancer

Several notable new trials from major sponsors and local institutions are now accepting participants:

• Incyte Corporation is sponsoring NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of a new combination therapy.
• Boehringer Ingelheim is initiating NCT07544654, "A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy." This Phase 3 study is open to adults with advanced extrapulmonary neuroendocrine cancer and aims for 390 participants to find out if a study medicine called obrixtamig improves survival when combined with standard chemotherapy.
• Caliway Biopharmaceuticals Co., Ltd. is sponsoring NCT07526974, "A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )." This Phase 3, randomized, double-blinded, placebo-controlled study will evaluate CBL-514 injection for reducing abdominal subcutaneous fat in 320 participants.
• Pfizer is launching NCT07519655, "Phase 1 Study of PF-08046033 in Advanced Solid Tumors." This early-stage (Phase 1) clinical study aims for 250 participants to test a new study medicine, focusing on its safety, tolerability, and early signs of efficacy in treating cancer.
• Vanderbilt University Medical Center is sponsoring NCT07536984, "Examination of Personalized SpO2 Targets." This large observational study aims for 3,000 participants to investigate the optimal arterial oxygen saturation (SpO2) target for critically ill adults undergoing mechanical ventilation.

Healthy Volunteer Opportunities

For individuals without a specific medical condition, there are opportunities to contribute to medical research. Of the 13 new trials launched this month, 1 is actively seeking healthy volunteers. Across Nashville, a total of 75 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Nashville's Leading Research Hubs

Nashville is home to prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Vanderbilt University Medical Center (313 trials)
• SCRI Oncology Partners (101 trials)
• Vanderbilt University/Ingram Cancer Center (93 trials)
• Sarah Cannon Research Institute (63 trials)
• Tennessee Oncology (51 trials)
• Vanderbilt University (49 trials)
• Research Site (42 trials)
• Vanderbilt-Ingram Cancer Center (38 trials)
• The Children's Hospital at TriStar Centennial (28 trials)
• Tennessee Oncology, PLLC (14 trials)
• Monroe Carell Jr. Children's Hospital at Vanderbilt (14 trials)
• Vanderbilt Breast Center at One Hundred Oaks (14 trials)

Vanderbilt-affiliated facilities collectively lead the research landscape in Nashville, with a strong emphasis on oncology and specialized care. Institutions like SCRI Oncology Partners, Sarah Cannon Research Institute, and Tennessee Oncology also play significant roles, particularly in cancer research.

Expanding Your Search: Nearby Tennessee Cities

While Nashville offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Tennessee. Cities with active trials include Memphis (7 trials), Chattanooga (1 trial), Knoxville (1 trial), Murfreesboro (1 trial), and Smyrna (1 trial).

Who Can Participate?

Participation in clinical trials is open to a diverse range of individuals. Of the new trials launched this month, 11 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 3 new trials are specifically designed for children, 1 is female-only, and 1 is male-only. Academic institutions, notably Vanderbilt University Medical Center, continue to drive a significant portion of research, alongside industry sponsors like Boehringer Ingelheim, Caliway Biopharmaceuticals Co., Ltd., and Pfizer.

As we move further into spring, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the continued exploration of new therapeutic strategies, with Nashville's robust research community at the forefront of medical innovation.